MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Home・Stock List・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Closed

SectorHealthcare

12.07 -0.49

Buy Sell

Overview

Share price change

24h

Current

Min

11.88

Max

13.16

Key metrics
By Trading Economics
Income	11M -20M
Sales	5.9M 40M
Profit margin	-49.569
Employees	184
EBITDA	16M -19M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+95.79% upside

Dividends
By Dow Jones
Next Earnings	24 Feb 2026

Market Stats
By TradingEconomics
Market Cap	294M 1B
Previous open	12.56
Previous close	12.07

News Sentiment

By Acuity

50%

177 / 360 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

6.26 / 7.47 Support & Resistance

Day One Biopharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

21 Jan 2026, 23:49 UTC

Major Market Movers

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 Jan 2026, 21:12 UTC

Major Market Movers

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 Jan 2026, 21:00 UTC

Acquisitions, Mergers, Takeovers

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 Jan 2026, 20:29 UTC

Major Market Movers

Chip Makers Gain After Trump Calls Off European Tariffs

21 Jan 2026, 20:04 UTC

Major Market Movers

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 Jan 2026, 23:48 UTC

Market Talk

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 Jan 2026, 23:34 UTC

Market Talk

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 Jan 2026, 22:39 UTC

Earnings

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 Jan 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21 Jan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 Jan 2026, 21:35 UTC

Acquisitions, Mergers, Takeovers

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 Jan 2026, 21:19 UTC

Earnings

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 Jan 2026, 20:45 UTC

Acquisitions, Mergers, Takeovers

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 Jan 2026, 20:36 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 Jan 2026, 20:31 UTC

Market Talk

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 Jan 2026, 20:27 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 Jan 2026, 20:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 Jan 2026, 20:27 UTC

Market Talk

Was It a 'TACO' Event? -- Market Talk

21 Jan 2026, 20:26 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 Jan 2026, 20:23 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 Jan 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 Jan 2026, 20:19 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse Group Agrees to Buy Allfunds

21 Jan 2026, 20:08 UTC

Earnings

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 Jan 2026, 20:03 UTC

Market Talk

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 Jan 2026, 19:51 UTC

Market Talk

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 Jan 2026, 19:43 UTC

Market Talk

U.S. Ethanol Production Expected to Slip -- Market Talk

21 Jan 2026, 19:31 UTC

Market Talk

Gold Settles at Fresh All-Time High -- Market Talk

21 Jan 2026, 19:24 UTC

Earnings

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 Jan 2026, 19:10 UTC

Market Talk

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 Jan 2026, 18:57 UTC

Market Talk

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Peer Comparison

Price change

Day One Biopharmaceuticals Inc Forecast

Price Target

By TipRanks

95.79% upside

12 Months Forecast

Average 23.71 USD 95.79%

High 34 USD

Low 16 USD

Based on 9 Wall Street analysts offering 12 month price targets forDay One Biopharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Day One Biopharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

6.26 / 7.47Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

177 / 360 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.